Go Pro
→ These gold assets are priced for $1,800 gold [it's over $4,000] (From Golden Portfolio) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
PaxMedica, Inc. stock logo
PXMD
PaxMedica
$0.00
$0.00
$0.00
▼
$0.02
$6K-0.994,577 shsN/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
$0.00
$0.00
$0.00
▼
$0.02
$11K1.3115,534 shs30,100 shs
Trevena, Inc. stock logo
TRVN
Trevena
$0.01
$0.00
$0.00
▼
$1.50
$11K-0.55726 shs44 shs
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
$0.01
$0.00
▼
$0.10
$14K-16.551,322 shs14 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
PaxMedica, Inc. stock logo
PXMD
PaxMedica
0.00%0.00%0.00%0.00%+400.00%
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
0.00%0.00%+300.00%+300.00%+300.00%
Trevena, Inc. stock logo
TRVN
Trevena
0.00%+2,700.00%+1,020.00%+646.67%+12.00%
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
0.00%+11,000.00%+5,450.00%0.00%-55.78%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
PaxMedica, Inc. stock logo
PXMD
PaxMedica
$0.00
$0.00
$0.00
▼
$0.02
$6K-0.994,577 shsN/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
$0.00
$0.00
$0.00
▼
$0.02
$11K1.3115,534 shs30,100 shs
Trevena, Inc. stock logo
TRVN
Trevena
$0.01
$0.00
$0.00
▼
$1.50
$11K-0.55726 shs44 shs
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
$0.01
$0.00
▼
$0.10
$14K-16.551,322 shs14 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
PaxMedica, Inc. stock logo
PXMD
PaxMedica
0.00%0.00%0.00%0.00%+400.00%
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
0.00%0.00%+300.00%+300.00%+300.00%
Trevena, Inc. stock logo
TRVN
Trevena
0.00%+2,700.00%+1,020.00%+646.67%+12.00%
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
0.00%+11,000.00%+5,450.00%0.00%-55.78%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
PaxMedica, Inc. stock logo
PXMD
PaxMedica
0.00
N/AN/AN/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
0.00
N/AN/AN/A
Trevena, Inc. stock logo
TRVN
Trevena
0.00
N/AN/AN/A
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
PaxMedica, Inc. stock logo
PXMD
PaxMedica
N/AN/AN/AN/A$0.46 per shareN/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
$386K0.03N/AN/A$0.79 per share0.00
Trevena, Inc. stock logo
TRVN
Trevena
$443K0.02N/AN/A($11.07) per share0.00
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
N/AN/AN/AN/A$1.65 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
PaxMedica, Inc. stock logo
PXMD
PaxMedica
-$18.29M-$6.09N/AN/AN/AN/A-3,167.89%-560.35%12/2/2026 (Estimated)
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
-$164.57M-$3.03N/AN/AN/AN/A-3,369.56%-97.04%10/29/2026 (Estimated)
Trevena, Inc. stock logo
TRVN
Trevena
-$40.29M-$47.04N/AN/AN/AN/AN/A-119.55%11/5/2026 (Estimated)
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
-$15.19M-$123.25N/AN/AN/AN/A-1,554.34%-338.29%11/19/2026 (Estimated)
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
PaxMedica, Inc. stock logo
PXMD
PaxMedica
N/AN/AN/AN/AN/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
N/AN/AN/AN/AN/A
Trevena, Inc. stock logo
TRVN
Trevena
N/AN/AN/AN/AN/A
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
PaxMedica, Inc. stock logo
PXMD
PaxMedica
N/A
0.38
0.38
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
N/A
2.25
2.25
Trevena, Inc. stock logo
TRVN
Trevena
N/A
2.42
2.42
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
N/A
0.13
0.13

Institutional Ownership

CompanyInstitutional Ownership
PaxMedica, Inc. stock logo
PXMD
PaxMedica
4.90%
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
91.47%
Trevena, Inc. stock logo
TRVN
Trevena
13.56%
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
32.23%

Insider Ownership

CompanyInsider Ownership
PaxMedica, Inc. stock logo
PXMD
PaxMedica
1.00%
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
12.26%
Trevena, Inc. stock logo
TRVN
Trevena
2.70%
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
3.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
PaxMedica, Inc. stock logo
PXMD
PaxMedica
611.31 million11.20 millionNot Optionable
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
6826.83 million23.54 millionNo Data
Trevena, Inc. stock logo
TRVN
Trevena
23959,000841,000No Data
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
21.24 million4.71 millionNot Optionable

Recent News About These Companies

Virpax Pharmaceuticals stock plummets on Nasdaq delisting news
April 3, 2025  |  investing.comhttps://www.investing.com/news/stock-market-news/virpax-pharmaceuticals-stock-plummets-on-nasdaq-delisting-news-93CH-3966072
Virpax Pharmaceuticals Inc trading halted, news pending
March 21, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/virpax-pharmaceuticals-inc-trading-halted-news-pending-1034500708
Virpax reports positive results in Probudur dog study
March 20, 2025  |  investing.comhttps://www.investing.com/news/company-news/virpax-reports-positive-results-in-probudur-dog-study-93CH-3935131
Virpax receives positive Probudur results for dose range study
March 20, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/virpax-receives-positive-probudur-results-for-dose-range-study-1034490634
Virpax Pharmaceuticals announces 1-for-25 reverse stock split
March 20, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/virpax-pharmaceuticals-announces-1-for-25-reverse-stock-split-1034494202
Virpax Receives Positive Probudur™ Results for Dose Range Study Moves Towards Next Steps in IND
March 18, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/virpax-receives-positive-probudur-results-200100643.html
Virpax Pharmaceuticals files to sell common stock and warrants, no amount given
March 18, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/virpax-pharmaceuticals-files-to-sell-common-stock-and-warrants-no-amount-given-1034485903
Virpax Pharmaceuticals Explores Intranasal mRNA Vaccine Delivery Using MET
March 11, 2025  |  msn.comhttps://www.msn.com/en-us/health/other/virpax-pharmaceuticals-explores-intranasal-mrna-vaccine-delivery-using-met/ar-AA1AGDwC
Virpax Pharmaceuticals to Present NES100 Toxicity Study at Major Toxicology Conference
March 11, 2025  |  msn.comhttps://www.msn.com/en-us/health/other/virpax-pharmaceuticals-to-present-nes100-toxicity-study-at-major-toxicology-conference/ar-AA1AF8g0
Virpax Looking to Use MET to Develop Intranasal COVID Vaccine
March 7, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250307334228/en/virpax-looking-to-use-met-to-develop-intranasal-covid-vaccine/
Analysts Conflicted on These Healthcare Names: Clearside Biomedical (CLSD) and Virpax Pharmaceuticals (VRPX)
March 6, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/analysts-conflicted-on-these-healthcare-names-clearside-biomedical-clsd-and-virpax-pharmaceuticals-vrpx-1034450215
Virpax’s NES100 to be Presented at The Society of Toxicology by NCATS
March 5, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/virpax-nes100-presented-society-toxicology-210100662.html
Virpax Pharmaceuticals Applauds Successful Trial of Molecular Envelope Technology
March 3, 2025  |  msn.comhttps://www.msn.com/en-us/money/savingandinvesting/virpax-pharmaceuticals-applauds-successful-trial-of-molecular-envelope-technology/ar-AA1A7VRw
Virpax lauds Nanomerics’ MET study with no severe side effects
March 1, 2025  |  investing.comhttps://www.investing.com/news/company-news/virpax-lauds-nanomerics-met-study-with-no-severe-side-effects-93CH-3897728
Virpax Reports Positive Results in Human Study for its Molecular Envelope Technology
February 27, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/virpax-reports-positive-results-human-210100424.html
Virpax Reports Positive Results in Human Study for its Molecular Envelope Technology
February 27, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250227128970/en/virpax-reports-positive-results-in-human-study-for-its-molecular-envelope-technology/
Virpax Confirms Positive Results with US Army with Probudur™ for Combat Care Study
February 13, 2025  |  joplinglobe.comJ
Virpax Pharmaceuticals confirms results with U.S. Army with Probudur
February 13, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/virpax-pharmaceuticals-confirms-results-with-u-s-army-with-probudur-1034358717
Virpax reports positive study results for pain management drug
February 13, 2025  |  msn.comhttps://www.msn.com/en-us/money/general/virpax-reports-positive-study-results-for-pain-management-drug/ar-AA1z0EUb
Virpax Pharmaceuticals appoints new independent director
February 6, 2025  |  msn.comhttps://www.msn.com/en-us/money/general/virpax-pharmaceuticals-appoints-new-independent-director/ar-AA1yywrg

New MarketBeat Followers Over Time

Media Sentiment Over Time

PaxMedica stock logo

PaxMedica NASDAQ:PXMD

$0.0005 0.00 (0.00%)
As of 09/23/2026

PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. Its lead product candidate is PAX-101 that is in Phase 3 clinical trials, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, fragile X syndrome, human African trypanosomiasis (HAT), and fragile X-associated tremor/ataxia syndrome. The company is developing PAX-102, an intranasal formulation of suramin for neurologic indications, as well as other new chemical entities that are targeted and selective antagonists of purine receptor subtypes; and PAX-HAT-301 for the treatment of HAT. It has a research collaboration agreement with PolarMar Health for Phase II clinical trial in austism spectrum disorder for emodin, which retains the rights for PolarMar to develop and commercialize any non-prescription supplement form of the product, and for PaxMedica, Inc. to retain exclusive rights to develop and commercialize a highly purified form of emodin. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York.

Syros Pharmaceuticals stock logo

Syros Pharmaceuticals NASDAQ:SYRS

$0.0004 0.00 (0.00%)
As of 03:37 PM Eastern

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

Trevena stock logo

Trevena NASDAQ:TRVN

$0.01 0.00 (0.00%)
As of 09/23/2026

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.

Virpax Pharmaceuticals stock logo

Virpax Pharmaceuticals NASDAQ:VRPX

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas